Sex specific efficacy and safety outcomes in operable stage III non-small cell lung cancer (NSCLC): Pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14

被引：0

作者：

Frehner, L. ^{[1
]}

Schaer, S. ^{[2
]}

Hayoz, S. ^{[2
]}

Guckenberger, M. ^{[3
]}

Finazzi, T. ^{[4
]}

Mark, M. T. ^{[5
]}

Addeo, A. ^{[6
]}

Mauti, L. A. ^{[7
]}

Betticher, D. C. ^{[8
]}

Stupp, R. ^{[9
]}

Curioni-Fontecedro, A. ^{[10
]}

Peters, S. ^{[11
]}

Frueh, M. ^{[12
]}

Rothschild, S. I. ^{[13
,14
]}

Pless, M.

Koenig, D. ^{[15
]}

Schmitt-Opitz, I. ^{[16
]}

Ris, H-B. ^{[17
]}

Ozdemir, B. C. ^{[1
]}

Schmid, S. ^{[1
]}

机构：

[1] Univ Bern, Univ Hosp Bern, Inselspital, Dept Med Oncol, Bern, Switzerland

[2] Swiss Grp Clin Canc Res SAKK Competence Ctr, Stat, Bern, Switzerland

[3] Univ Zurich, Univ Zurich Hosp, Dept Radiat Oncol, Zurich, Switzerland

[4] Univ Hosp Basel, Clin Radiotherapy & Radiat Oncol, Basel, Switzerland

[5] Cantonal Hosp Graubuenden, Div Hematol Oncol, Chur, Switzerland

[6] Univ Hosp Geneva, Dept Oncol, Geneva, Switzerland

[7] Kantonsspital Winterthur, Dept Med Oncol, Winterthur, Switzerland

[8] Univ Fribourg, Cantonal Hosp Fribourg, Clin Oncol, Villars Sur Glane, Switzerland

[9] Northwestern Univ, Feinberg Sch Med, Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[10] Univ Fribourg, Cantonal Hosp Fribourg, Clin Oncol, Villar Sur Glane, Switzerland

[11] Ctr Hosp Univ Vaudois CHUV, Dept Oncol, Lausanne, Switzerland

[12] Kantonsspital St Gallen, Dept Med Oncol & Hematol, St Gallen, Switzerland

[13] Cantonal Hosp Baden, Ctr Oncol Hematol, Baden, Switzerland

[14] Cantonal Hosp Baden, Ctr Comprehens Canc, Baden, Switzerland

[15] Univ Hosp Basel, Dept Med Oncol, Basel, Switzerland

[16] Univ Zurich, Univ Zurich Hosp, Dept Thorac Surg, Zurich, Switzerland

[17] Hop Valais, Clin Thorac Surg, Sion, Switzerland

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1282

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1223P

引用

页码：S786 / S786

页数：1

共 50 条

[1] Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials
Koenig, D.
Schaer, S.
Vuong, D.
Guckenberger, M.
Furrer, K.
Opitz, I
Weder, W.
Rothschild, S., I
Ochsenbein, A.
Zippelius, A.
Addeo, A.
Mark, M.
Eboulet, E., I
Hayoz, S.
Thierstein, S.
Betticher, D. C.
Ris, H-B
Stupp, R.
Curioni-Fontecedro, A.
Peters, S.
Pless, M.
Frueh, M.
ESMO OPEN, 2022, 7 (02)
[2] Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)
Fruh, Martin
Betticher, Daniel C.
Stupp, Roger
Xyrafas, Alexandros
Peters, Solange
Ris, Hans Beat
Mirimanoff, Rene Olivier
Ochsenbein, Adrian F.
Schmid, Ralph
Matzinger, Oscar
Stahel, Rolf A.
Weder, Walter
Guckenberger, Matthias
Rothschild, Sacha I.
Lardinois, Didier
Mach, Nicholas
Mark, Michael
Gautschi, Oliver
Thierstein, Sandra
Rudolf, Christine Biaggi
Pless, Miklos
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (01) : 115 - 123
[3] Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials (vol 7, 100455, 2022)
Konig, D.
Schar, S.
Vuong, D.
Guckenberger, M.
Furrer, K.
Opitz, I.
Weder, W.
Rothschild, S. I.
Ochsenbein, A.
Zippelius, A.
Addeo, A.
Mark, M.
Eboulet, E. I.
Hayoz, S.
Thierstein, S.
Betticher, D. C.
Ris, H. -B.
Stupp, R.
Curioni-Fontecedro, A.
Peters, S.
Pless, M.
Fruh, M.
ESMO OPEN, 2022, 7 (03)
[4] Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small cell lung cancer. Retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01 and 16/14.
Konig, D.
Prince, S. Savic
Hayoz, S.
Zens, P.
Berezowska, S.
Jochum, W.
Stauffer, E.
Braunersreuther, V.
Trachsel, B.
Thierstein, S.
Mark, M.
Schmid, S.
Opitz, I.
Guckenberger, M.
Fruh, M.
Betticher, D. C.
Ris, H. -B.
Stupp, R.
Rothschild, S. I.
Bubendorf, L.
Pless, M.
SWISS MEDICAL WEEKLY, 2022, 152 : 17S - 18S
[5] Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14
Konig, D.
Prince, S. Savic
Hayoz, S.
Zens, P.
Berezowska, S.
Jochum, W.
Stauffer, E.
Braunersreuther, V.
Trachsel, B.
Thierstein, S.
Mark, M.
Schmid, S.
Curioni-Fontecedro, A.
Addeo, A.
Opitz, I.
Guckenberger, M.
Frueh, M.
Betticher, D. C.
Ris, H. -b.
Stupp, R.
Rothschild, S. I.
Bubendorf, L.
Pless, M.
ESMO OPEN, 2023, 8 (04)
[6] Extended Resections for Advanced Stages T3/T4 NSCLC After Neoadjuvant Treatment: Conclusions of SAKK Pooled Analysis (16/96,16/00,16/01)
Furrer, K.
Weder, W.
Eboulet, E.
Betticher, D.
Pless, M.
Stupp, R.
Krueger, T.
Perentes, J. Y.
Schmid, R.
Lardinois, D.
Furrer, M.
Fruh, M.
Peters, S.
Curioni-Fontecedro, A.
Stahel, R.
Rothschild, S.
Hayoz, S.
Thierstein, S.
Biaggi, C.
Opitz, I.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1051 - S1051
[7] Rb and p16 expression in non-small cell lung cancer (NSCLC).
Flieder, DB
Brambilla, E
Rush, W
Przygodzki, R
Fleming, M
Freedman, A
Travis, W
Caporaso, N
Guinee, D
Bennett, W
Jones, R
Trastek, V
Pairolero, P
Tazelaar, H
Jett, J
Midthun, D
Liotta, L
Harris, CC
MODERN PATHOLOGY, 1998, 11 (01) : 173A - 173A
[8] Preoperative Chemotherapy Is Effective for Stage III Resectable Non-Small-Cell Lung Cancer: Metaanalysis of 16 Trials
Horita, Nobuyuki
Miyazawa, Naoki
Morita, Satoshi
Kojima, Ryota
Kimura, Naoko
Kaneko, Takeshi
Ishigatsubo, Yoshiaki
CLINICAL LUNG CANCER, 2013, 14 (05) : 488 - 494
[9] Characterizing the tumor microbiome of non-small cell lung cancer patients receiving neoadjuvant chemo-immunotherapy (SAKK 16/14)
Boesch, Maximilian
Baty, Florent
Rothschild, Sacha
Alborelli, Ilaria
Keller, Eveline
Savic, Spasenija
Hayoz, Stefanie
Joerger, Markus
Fruh, Martin
Brutsche, Martin
EUROPEAN RESPIRATORY JOURNAL, 2024, 64
[10] Non-small Cell Lung Cancer: Aleast 16 Lymph Nodes removed
Lorenz, Judith
ZENTRALBLATT FUR CHIRURGIE, 2018, 143 (01):

← 1 2 3 4 5 →